{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:21:40Z","timestamp":1790490100715,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HIV-1 reservoirs persist in the presence of combined antiretroviral therapy (cART). However, cART has transformed HIV-1 infection into a chronic disease marked by control of HIV-1 viral load and mortality reduction. Major challenges remain, including viral resistance upon termination of cART and persistence and identification of tissue distribution of HIV-1 reservoirs. Thus, appropriate animal models that best mimic HIV-1 pathogenesis are important, and the current study complements our previously published validation of the CD34+ hematopoietic humanized mouse model for this purpose. Here we analyze viral suppression using the recently developed combination of antiretrovirals that include Tenofovir Disoproxil (TDF), Emtricitabine (FTC), and Dolutegravir (DTG), a choice based on recent clinical outcomes showing its improved antiretroviral potency, CD4+ T cell preservation, tolerability, and prevention of viral drug resistance compared to that of previous regimens. We used quantitative Airyscan-based super resolution confocal microscopy of selected mouse tissues. Our data allowed us\u00a0to identify specific solid tissue reservoirs of human T\u00a0cells expressing the HIV-1 core protein p24. In particular, lymph node, brain, spleen, and liver were visualized as reservoirs for residual infected cells. Marked reduction of viral replication was evident. Considering that detection and visualization of cryptic sites of HIV-1 infection in tissues are clearly crucial steps towards HIV-1 eradication, appropriate animal models with pseudo-human immune systems are needed. In fact, current studies with humans and non-human primates have limited sample availability at multiple stages of infection and cannot easily analyze the effects of differently administered combined antiretroviral treatments on multiple tissues. That is easier to manage when working with humanized mouse models, although we realize the limitations due to low human cell recovery and thus the number of cells available for thorough and comprehensive analyses. Nonetheless, our data further confirm that the CD34+ humanized mouse model is a potentially useful pre-clinical model to study and improve current anti-HIV-1 therapies.<\/jats:p>","DOI":"10.1186\/s12967-021-03120-w","type":"journal-article","created":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T17:02:33Z","timestamp":1635613353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice"],"prefix":"10.1186","volume":"19","author":[{"given":"Matthew","family":"Weichseldorfer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Affram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonso","family":"Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Rikhtegaran-Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad M.","family":"Sajadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiko P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Tagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib O.","family":"Ramadhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshi","family":"Munawwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Zella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Reitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Romerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga S.","family":"Latinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,30]]},"reference":[{"issue":"8","key":"3120_CR1","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","volume":"15","author":"N Chomont","year":"2009","unstructured":"Chomont N, El-Far M, Ancuta P, Trautmann L, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15(8):893\u2013900.","journal-title":"Nat Med"},{"issue":"10","key":"3120_CR2","doi-asserted-by":"publisher","first-page":"e1002288","DOI":"10.1371\/journal.ppat.1002288","volume":"7","author":"A Bosque","year":"2011","unstructured":"Bosque A, Famiglietti M, Weyrich AS, et al. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PloS Pathog. 2011;7(10):e1002288.","journal-title":"PloS Pathog"},{"key":"3120_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60104-X","author":"C Katlama","year":"2013","unstructured":"Katlama C, Deeks SG, Autran B, et al. Barriers to a cure: new concepts in targeting and eradicating HIV-1 reservoirs. Lancet. 2013. https:\/\/doi.org\/10.1016\/S0140-6736(13)60104-X.","journal-title":"Lancet"},{"key":"3120_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0140-6736(05)76156-0","volume":"353","author":"V Natarajan","year":"1999","unstructured":"Natarajan V, Bosche M, Metcalf JA, Ward DJ, Lane HC, Kovacs JA. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet. 1999;353:119\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(05)76156-0.","journal-title":"Lancet"},{"key":"3120_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/COH.0000000000000287","volume":"11","author":"J Martinez-Picado","year":"2016","unstructured":"Martinez-Picado J, Deeks SG. Persistent HIV-1 replication during antiretroviral therapy. Curr Opin HIV AIDS. 2016;11:417\u201323. https:\/\/doi.org\/10.1097\/COH.0000000000000287.","journal-title":"Curr Opin HIV AIDS"},{"key":"3120_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2013.09.020","volume":"155","author":"YC Ho","year":"2013","unstructured":"Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155:540\u201351. https:\/\/doi.org\/10.1016\/j.cell.2013.09.020.","journal-title":"Cell"},{"key":"3120_CR7","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1126\/science.1165706","volume":"323","author":"DD Richman","year":"2009","unstructured":"Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science. 2009;323:1304\u20137. https:\/\/doi.org\/10.1126\/science.1165706.","journal-title":"Science"},{"key":"3120_CR8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s11908-014-0392-2","volume":"16","author":"DM Margolis","year":"2014","unstructured":"Margolis DM. How might we cure HIV? Curr Infect Dis Rep. 2014;16:392. https:\/\/doi.org\/10.1007\/s11908-014-0392-2.","journal-title":"Curr Infect Dis Rep"},{"key":"3120_CR9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1126\/science.3277272","volume":"239","author":"RW Price","year":"1988","unstructured":"Price RW, Brew B, Sidtis J, et al. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science. 1988;239:586\u201392. https:\/\/doi.org\/10.1126\/science.3277272.","journal-title":"Science"},{"key":"3120_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1128\/JVI.73.1.352-361.1999","volume":"73","author":"PR Gorry","year":"1999","unstructured":"Gorry PR, Howard JL, Churchill MJ, et al. Diminished production of human immunodeficiency virus type 1 in astrocytes results from inefficient translation of gag, env, and nef mRNAs despite efficient expression of Tat and Rev. J Virol. 1999;73:352\u201361.","journal-title":"J Virol"},{"key":"3120_CR11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1172\/JCI84456","volume":"126","author":"JB Honeycutt","year":"2016","unstructured":"Honeycutt JB, Wahl A, Baker C, et al. Macrophages sustain HIV replication in vivo independently of T cells. J Clin Invest. 2016;126:1353\u201366. https:\/\/doi.org\/10.1172\/JCI84456.","journal-title":"J Clin Invest"},{"issue":"12","key":"3120_CR12","doi-asserted-by":"publisher","first-page":"a007443","DOI":"10.1101\/cshperspect.a007443","volume":"2","author":"R Swanstrom","year":"2012","unstructured":"Swanstrom R, Coffin J. HIV-1 pathogenesis: the virus. Cold Spring Harb Perspect Med. 2012;2(12):a007443.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3120_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nature16933","volume":"530","author":"R Lorenzo-Redondo","year":"2016","unstructured":"Lorenzo-Redondo R, Fryer HR, Bedford T, et al. Persistent HV-1 replication maintains the tissue reservoir during therapy. Nature. 2016;530:51\u201363.","journal-title":"Nature"},{"key":"3120_CR14","doi-asserted-by":"publisher","first-page":"23513","DOI":"10.1038\/srep23513","volume":"6","author":"M Arainga","year":"2016","unstructured":"Arainga M, Su H, Poluektova LY, et al. HIV-1 cellular and tissue replication patterns in infected humanized mice. Sci Rep. 2016;6:23513.","journal-title":"Sci Rep"},{"key":"3120_CR15","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1523\/JNEUROSCI.5473-10.2011","volume":"31","author":"PK Dash","year":"2011","unstructured":"Dash PK, Gorantla S, Gendelman HE, et al. Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci. 2011;31:3148\u201357.","journal-title":"J Neurosci"},{"key":"3120_CR16","first-page":"w12618","volume":"142","author":"M Nischan","year":"2012","unstructured":"Nischan M, Gers-Huber G, Audige A, et al. Modeling HIV infection and therapies in humanized mice. Swiss Med Wkly. 2012;142:w12618.","journal-title":"Swiss Med Wkly"},{"key":"3120_CR17","first-page":"786","volume":"12","author":"LD Shultz","year":"2012","unstructured":"Shultz LD, Brehm MA, Garcia-Martinez JV, et al. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev. 2012;12:786\u201398.","journal-title":"Nat Rev"},{"key":"3120_CR18","doi-asserted-by":"publisher","first-page":"e02118","DOI":"10.1128\/JVI.02118-17","volume":"92","author":"S Satheesan","year":"2018","unstructured":"Satheesan S, Haitang L, Burnett JC, et al. HIV Replication and latency in a humanized NSG mouse model during suppressive oral combinational antiretroviral therapy. J Virol. 2018;92:e02118-e2217.","journal-title":"J Virol"},{"issue":"1","key":"3120_CR19","first-page":"23","volume":"2","author":"M Weichseldorfer","year":"2020","unstructured":"Weichseldorfer M, Heredia A, Reitz M, et al. Use of humanized mouse models for studying HIV-1 infection pathogenesis and persistence. J AIDS HIV Treat. 2020;2(1):23\u20139.","journal-title":"J AIDS HIV Treat"},{"issue":"5","key":"3120_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.immuni.2018.04.030","volume":"48","author":"S Sengupta","year":"2018","unstructured":"Sengupta S, Siliciano RF. Targeting the latent reservoir for HIV-1. Immunity. 2018;48(5):872\u201395.","journal-title":"Immunity"},{"issue":"1","key":"3120_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S2055-6640(20)30275-2","volume":"5","author":"J Vanhamel","year":"2019","unstructured":"Vanhamel J, Bruggemans A, Debyser Z. Establishment of latent HIV-1 reservoirs: what do we really know? J Virus Erad. 2019;5(1):3\u20139.","journal-title":"J Virus Erad"},{"issue":"6","key":"3120_CR22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/COH.0000000000000108","volume":"9","author":"LR Gray","year":"2014","unstructured":"Gray LR, Roche M, Flynn JK, et al. Is the central nervous system a reservoir of HIV-1? Curr Opin HIV AIDS. 2014;9(6):552\u20138.","journal-title":"Curr Opin HIV AIDS"},{"issue":"8","key":"3120_CR23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1089\/aid.2018.0305","volume":"35","author":"OS Latinovic","year":"2019","unstructured":"Latinovic OS, Neal LM, Tagaya Y, et al. Suppression of active HIV-1 infection in CD34+ hematopoietic humanized NSG mice by a combination of combined antiretroviral therapy and CCR5 targeting drugs. AIDS Res Hum Retrovir. 2019;35(8):718\u201328.","journal-title":"AIDS Res Hum Retrovir"},{"key":"3120_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","volume":"382","author":"P Cahn","year":"2013","unstructured":"Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700\u20138.","journal-title":"Lancet"},{"issue":"32","key":"3120_CR25","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1097\/MD.0000000000016721","volume":"98","author":"TT Brehm","year":"2019","unstructured":"Brehm TT, Franz M, Hufner A, et al. Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-na\u00efve and -experienced patients. Medicine. 2019;98(32):e167.","journal-title":"Medicine"},{"key":"3120_CR26","first-page":"339","volume":"8","author":"H Taha","year":"2015","unstructured":"Taha H, Das A, Das S. Clinical effectiveness of dolutegravir in the treatment of HIV\/AIDS. Infect Drug Resist. 2015;8:339\u201352.","journal-title":"Infect Drug Resist"},{"key":"3120_CR27","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/QAD.0000000000001447","volume":"31","author":"JW McAllister","year":"2017","unstructured":"McAllister JW, Towns JM, Mcnulty A, et al. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men. AIDS. 2017;31:1291\u20135.","journal-title":"AIDS"},{"key":"3120_CR28","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","volume":"13","author":"F Raffi","year":"2013","unstructured":"Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13:927\u201335.","journal-title":"Lancet Infect Dis"},{"key":"3120_CR29","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1093\/jac\/dkq350","volume":"65","author":"WG Powderly","year":"2010","unstructured":"Powderly WG. Integrase inhibitors in the treatment of HIV-1 infection. J Antimicrob Chemother. 2010;65:2485\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"3120_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"EDF Venter","year":"2019","unstructured":"Venter EDF, Moorhouse S, Sokhela L, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803\u201315.","journal-title":"N Engl J Med"},{"key":"3120_CR31","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV."},{"key":"3120_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12977-017-0344-7","volume":"14","author":"M Arainga","year":"2017","unstructured":"Arainga M, Edagwa B, Mosley RL, et al. A mature macrophage is a principle HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology. 2017;14:17.","journal-title":"Retrovirology"},{"key":"3120_CR33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/infdis\/jiw203","volume":"214","author":"M Deruaz","year":"2016","unstructured":"Deruaz M, Moldt B, Le KM, Power KA, Vrbanac VD, Tanno S, Ghebremichael MS, Allen TM, Tager AM, Burton DR, Luster AD. Protection of humanized mice from repeated intravaginal HIV challenge by passive immunization: a model for studying the efficacy of neutralizing antibodies in vivo. J Infect Dis. 2016;214:612\u20136.","journal-title":"J Infect Dis"},{"key":"3120_CR34","doi-asserted-by":"publisher","first-page":"5460","DOI":"10.1128\/JVI.01049-07","volume":"82","author":"BM Taylor","year":"2008","unstructured":"Taylor BM, Foulke JS, Flinko R, et al. An alternation of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence. J Virol. 2008;82:5460\u201371.","journal-title":"J Virol"},{"key":"3120_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13293-014-0015-5","volume":"5","author":"LD McCullough","year":"2014","unstructured":"McCullough LD, de Vries GJ, Miller VM, et al. NIH initiative to balance sex of animals in preclinical studies: generative questions to guide policy, implementation, and metrics. Biol Sex Differ. 2014;5:15.","journal-title":"Biol Sex Differ"},{"issue":"6","key":"3120_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038853","volume":"7","author":"M Nischang","year":"2012","unstructured":"Nischang M, Sutmuller R, Gers-Huber G, et al. Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1. PLoS ONE. 2012;7(6): e38853. https:\/\/doi.org\/10.1371\/journal.pone.0038853.","journal-title":"PLoS ONE"},{"issue":"9","key":"3120_CR37","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1093\/jac\/dkx195","volume":"72","author":"A Heredia","year":"2017","unstructured":"Heredia A, Hassounah S, Medina-Moreno S, et al. Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice. J Antimicrob Chemother. 2017;72(9):2570\u20133. https:\/\/doi.org\/10.1093\/jac\/dkx195.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"3120_CR38","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1089\/aid.2020.0064","volume":"36","author":"W Weichseldorfer","year":"2020","unstructured":"Weichseldorfer W, Affram Y, Heredia A, et al. Anti-HIV activity of standard cART in primary cells is intensified by CCR5-targeting drugs. AIDS Res Hum Retrovir. 2020;36(10):835\u201341.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"6","key":"3120_CR39","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1128\/JVI.02883-15","volume":"90","author":"S Pallikkuth","year":"2016","unstructured":"Pallikkuth S, Sharkey M, Pahwa S, et al. Peripheral T follicular helper cells are the major HIV reservoir within central memory CD4 T cells in peripheral blood from chronically HIV-infected individuals on combination antiretroviral therapy. J Virol. 2016;90(6):2718\u201328.","journal-title":"J Virol"},{"issue":"7","key":"3120_CR40","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1172\/JCI93289","volume":"127","author":"GQ Lee","year":"2017","unstructured":"Lee GQ, Orlova-Fink N, Einkauf K, et al. Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. J Clin Invest. 2017;127(7):2689\u201396. https:\/\/doi.org\/10.1172\/JCI93289.","journal-title":"J Clin Invest"},{"key":"3120_CR41","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1097\/QAD.0000000000000863","volume":"29","author":"P Tebas","year":"2015","unstructured":"Tebas P, Kumar P, Hicks C, et al. Greater change in bone turnover markers for efavirenz\/emtricitabine\/tenofovir disoproxil fumarate versus dolutegravir + abacavir\/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS. 2015;29:2459\u201364.","journal-title":"AIDS"},{"issue":"3","key":"3120_CR42","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/QAI.0000000000002454","volume":"85","author":"RK Acosta","year":"2020","unstructured":"Acosta RK, Willkom M, Andreatta K, et al. Switching to bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) from dolutegravir (DTG)+F\/TAF or DTG+F\/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance. J Acquir Immune Defic Syndr. 2020;85(3):363\u201371.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3120_CR43","first-page":"e1368","volume":"61","author":"E Garcia-Vadal","year":"2017","unstructured":"Garcia-Vadal E, Castelvi M, Pujantell M, et al. Evaluation of the innate immune modulator acitretin as a strategy to clear the HIV reservoir. Antimicrob Agents Chemother. 2017;61:e1368\u2013411.","journal-title":"Antimicrob Agents Chemother"},{"key":"3120_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","volume":"18","author":"T Cihlar","year":"2016","unstructured":"Cihlar T, Fordyce M. Current status and prospects of HIV treatment. Curr Opin Virol. 2016;18:50\u20136.","journal-title":"Curr Opin Virol"},{"key":"3120_CR45","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3389\/fonc.2018.00462","volume":"8","author":"BG Harder","year":"2018","unstructured":"Harder BG, Blomquist MR, Wang J, et al. Development in blood-brain barrier penetrance and drug repurposing for improved treatment of glioblastoma. Front Oncol. 2018;8:462.","journal-title":"Front Oncol"},{"issue":"11","key":"3120_CR46","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrmicro2223","volume":"7","author":"M Coiras","year":"2009","unstructured":"Coiras M, L\u00f3pez-Huertas MR, P\u00e9rez-Olmeda M, Alcam\u00ed J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol. 2009;7(11):798\u2013812.","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"3120_CR47","doi-asserted-by":"publisher","first-page":"e1008161","DOI":"10.1371\/journal.ppat.1008161","volume":"15","author":"JD Ventura","year":"2019","unstructured":"Ventura JD, Beloor J, Haugh KA, et al. Longitudinal bioluminescent imaging of HIV-1 infection during antiretroviral therapy and treatment interruption in humanized mice. PloS Pathog. 2019;15(12):e1008161.","journal-title":"PloS Pathog"},{"key":"3120_CR48","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.1038\/s41598-017-07307-4","volume":"7","author":"Y Satou","year":"2017","unstructured":"Satou Y, Katsuya H, Fukuda A, et al. Dynamics and mechanisms of clonal expansion of HIV-1-infected cells in a humanized mouse model. Sci Rep. 2017;7:6913.","journal-title":"Sci Rep"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-03120-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-021-03120-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-03120-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T17:06:53Z","timestamp":1635613613000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-021-03120-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,30]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3120"],"URL":"https:\/\/doi.org\/10.1186\/s12967-021-03120-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,30]]},"assertion":[{"value":"20 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animals were housed under pathogen-free conditions at the IHV Animal Facility, School of Medicine, University of Maryland (SOM UM) (Baltimore, MD). All experimental protocols were in accordance with the NIH guide for the care and use of laboratory animals and approved (Protocol #1215007) by the SOM UM IACUC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"453"}}